By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aileron Therapeutics 

281 Albany Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-995-0900 Fax: 617-995-2410



Company News
Aileron Therapeutics Announces Oral Presentation At ASCO On ALRN-6924 Targeting p53 5/18/2017 7:10:07 AM
Aileron Therapeutics Initiates Phase 1 Cancer Study Of ALRN-6924 In Advanced Hematologic And Solid Malignancies With Wild Type P53 2/12/2015 10:04:13 AM
Aileron Therapeutics Appoints Evan Lippman As Chief Financial And Business Officer 1/8/2015 10:52:30 AM
Aileron Therapeutics Expands Senior Management Team 10/29/2014 9:04:13 AM
MA BioPharma Aileron Therapeutics Locks In A Total Of $48 Million 10/29/2014 6:08:14 AM
Aileron Therapeutics To Present At Cowen and Company 34th Annual Health Care Conference On March 4, 2014 3/3/2014 7:24:28 AM
Aileron Therapeutics To Present At 2014 Leerink Swann and Company Global Healthcare Conference 2/10/2014 9:39:45 AM
Big Pharma Quartet Dumps $30 Million Behind Aileron Therapeutics' P53 Peptide Drug 11/18/2013 8:07:26 AM
Aileron Therapeutics Publishes Data Demonstrating ATSP-7041 as First-in-class p53 Pathway Re-activator for the Treatment of Solid and Hematologic Cancers 8/15/2013 10:45:31 AM
Aileron Therapeutics Successfully Completes First-Ever Stapled Peptide Clinical Trial 5/7/2013 11:01:34 AM